NASDAQ: EDSAEdesa Biotech Inc Stock
$7.64+0.83 (+12.19%)
Updated Jun 23, 2026
EDSA Price
$7.64
Fair Value Price
$1.90
Market Cap
$67.93M
52 Week Low
$0.72
52 Week High
$20.32
P/E
-5.7x
P/B
6.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$8M
Beta
0.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EDSA Overview
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EDSA's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EDSA
Ranked#417 of 467
Ranked#417 of 467
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.25 | A | |
| $51.34 | A | |
| $2.17 | A |
Be the first to know about important EDSA news, forecast changes, insider trades & much more!
EDSA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EDSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EDSA ($7.64) is overvalued by 301.87% relative to our estimate of its Fair Value price of $1.90 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EDSA ($7.64) is not significantly undervalued (301.87%) relative to our estimate of its Fair Value price of $1.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EDSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EDSA due diligence checks available for Premium users.
Valuation
EDSA fair value
Fair Value of EDSA stock based on Discounted Cash Flow (DCF)
Price
$7.64
Fair Value
$1.90
Overvalued by
301.87%
EDSA ($7.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EDSA ($7.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EDSA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EDSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.7x
Industry
15.59x
Market
7.68x
EDSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.66x
Industry
5.15x
EDSA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EDSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.2M
Profit Margin
0%
EDSA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.4M
Liabilities
$2.2M
Debt to equity
0.22
EDSA's short-term assets ($10.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EDSA's short-term assets ($10.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EDSA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EDSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
-$9.0k
EDSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EDSA vs Biotech Stocks
Edesa Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.